Alzheimer’s disease is a neurological disease, specifically a neurodegenerative one. It progressively damages and destroys neurons in the brain, starting with areas responsible for memory and gradually spreading to regions that control language, reasoning, and eventually basic physical functions. An estimated 7.1 million Americans are currently living with Alzheimer’s, making it the most common cause of dementia.
What “Neurodegenerative” Actually Means
Neurological diseases are any conditions affecting the nervous system, which includes the brain, spinal cord, and nerves throughout the body. Alzheimer’s falls into a more specific subcategory called neurodegenerative diseases, conditions that gradually damage and destroy parts of your nervous system. The “degenerative” part is key: the damage is progressive and, so far, irreversible. Other diseases in this category include Parkinson’s, ALS, and Lewy body dementia.
Because Alzheimer’s is a disease of the brain and nervous system, neurologists are the primary specialists involved in diagnosis and management. People with unclear symptoms, particularly those under 65, sometimes need evaluation by two or more specialists who combine their findings.
How Alzheimer’s Differs From Dementia
One common point of confusion is the relationship between Alzheimer’s and dementia. Dementia is not a disease. It’s an umbrella term describing a decline in mental ability severe enough to interfere with daily life, affecting memory, thinking, and behavior. Alzheimer’s is a specific biological disease that happens to be the most common cause of dementia. Other causes of dementia include vascular damage from strokes, Lewy body accumulation, and frontotemporal degeneration. Each has a different underlying process in the brain.
Since 2024, updated diagnostic criteria emphasize that Alzheimer’s should be defined biologically rather than by its symptoms alone. This means the disease is identified by measurable changes in the brain, not just by memory loss or confusion, which could stem from many causes.
What Happens Inside the Brain
Two types of abnormal protein buildup define Alzheimer’s at the cellular level. The first is amyloid plaques, which accumulate between nerve cells. The second is neurofibrillary tangles, twisted filaments that form inside neurons and are thought to be directly lethal to the cells they invade.
The tangles are made largely of a protein called tau. Under normal conditions, tau helps maintain the internal scaffolding that gives nerve cells their shape and allows them to transport nutrients. In Alzheimer’s, chemical modifications cause tau molecules to bunch together into clusters, then clumps, then full tangles. Research from Stanford Medicine has shown that a specific segment of the tau molecule becomes hundreds of times more prone to clumping after a particular chemical modification, and this modified form is the most common version of tau found in the tangles of Alzheimer’s patients.
Importantly, the number of neurofibrillary tangles in a person’s brain tracks closely with their degree of cognitive impairment, more so than amyloid plaques. This is why much of the newer treatment research focuses on tau rather than amyloid alone.
The damage typically starts in the entorhinal cortex and hippocampus, brain structures central to forming and retrieving memories. This is why memory loss is almost always the earliest noticeable symptom. Over time, the disease spreads outward to areas governing language, spatial awareness, judgment, and eventually basic motor functions.
Symptoms Across the Stages
Alzheimer’s is a continuum that begins long before anyone notices something is wrong. Brain changes associated with the disease can be present for years or even decades before symptoms appear, a phase called preclinical Alzheimer’s. During this time, there are no outward signs.
In the mild dementia stage, people typically experience memory loss of recent events, difficulty finding the right words, trouble organizing and expressing thoughts, and personality shifts. Someone who was previously outgoing may become withdrawn in social settings, or become unusually irritable. Reduced motivation to complete tasks is common.
As the disease progresses to moderate stages, more disorienting symptoms emerge. Some people become convinced that family members are stealing from them or that a spouse is being unfaithful. Others see or hear things that aren’t there. Restlessness and agitation tend to worsen, especially later in the day, and some individuals develop aggressive outbursts.
In severe dementia, mental function continues to decline and the disease increasingly affects physical capabilities, including movement, swallowing, and control of bodily functions.
Genetics and Risk
The most well-known genetic risk factor is a gene variant called APOE-e4. About 15% to 25% of people carry one copy, and 2% to 5% carry two copies. Having two copies raises the risk substantially and is associated with an earlier age of onset. On the other end, a variant called APOE-e2, carried by roughly 5% to 10% of people, appears to offer some protection. When Alzheimer’s does develop in someone with this variant, it tends to appear later in life.
A small number of cases are caused by rare mutations in three specific genes (APP, PSEN1, and PSEN2). If a parent carries one of these mutations, each child has a 50/50 chance of inheriting it, and those who do have a very strong probability of developing Alzheimer’s before age 65, sometimes much earlier. These early-onset cases account for less than 10% of all Alzheimer’s diagnoses.
How It’s Diagnosed Now
Diagnosis has shifted significantly in recent years. Updated 2024 criteria define Alzheimer’s as a biological continuum, diagnosed through biomarkers rather than symptoms alone. These biomarkers measure amyloid and tau levels and can be detected through brain imaging, spinal fluid analysis, or newer blood-based tests that have shown strong diagnostic accuracy. The ability to detect Alzheimer’s through a blood draw is relatively new and is still being validated for widespread clinical use.
The disease is understood as a spectrum: brain changes appear first, then gradually build until symptoms emerge and worsen. This means someone can have Alzheimer’s pathology in their brain without yet showing cognitive decline, though current guidelines do not recommend screening asymptomatic individuals outside of research settings.
Current Treatment Landscape
There is no cure for Alzheimer’s, but the treatment landscape has changed meaningfully. Newer therapies target amyloid plaques directly. One such treatment, lecanemab, is approved for adults with Alzheimer’s and works by clearing amyloid from the brain. After completing an initial 18-month course of intravenous infusions, patients can transition to injections administered at home by a caregiver.
These treatments slow the rate of cognitive decline rather than stopping or reversing it. They work best when started early in the disease, which is one reason the push toward earlier biomarker-based diagnosis matters so much. Projections estimate that more than 13.9 million Americans will be living with Alzheimer’s by 2060, roughly double the current number, making effective early intervention increasingly urgent.